Biohaven Crushes Forecasts; What’s Next For Its Blockbuster Hopeful?

Biohaven Pharmaceutical’s (BHVN) first-quarter pre-announcement for sales of migraine treatment Nurtec ODT crushed Wall Street’s expectations Wednesday, leading BHVN stock to surge.
XDuring the quarter, Nurtec ODT orally disintegrating tablets generated $43.8 million in sales, Biohaven said. That handily beat Bloomberg’s estimate for $27.2 million, Mizuho Securities analyst Difei Yang said in a report to clients.
Nurtec ODT launched recently as an acute migraine treatment. But analysts expect the…

Click here to view the original article.